@article{JTD6996,
author = {Takayuki Shiroyama and Motohiro Tamiya and Manabu Hayama and Takashi Nishihara and Takuji Nishida and Ayako Tanaka and Naoko Morishita and Hidekazu Suzuki and Norio Okamoto and Kunimitsu Kawahara and Tomonori Hirashima},
title = {A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {5},
year = {2016},
keywords = {},
abstract = {An 87-year-old man with postoperative recurrent lung adenocarcinoma was treated with gefitinib. At the beginning of treatment, surgically resected archived tumor tissue revealed a deletion in exon 19 of the EGFR gene, but no ALK gene rearrangement. After gefitinib treatment for 9 months, the disease progressed. Bronchoscopic rebiopsy was used to evaluate resistance mechanisms, and revealed lung adenocarcinoma with wild-type EGFR genes and a newly emerged ALK gene rearrangement. Treatment was switched to alectinib and a partial response was achieved within 4 weeks. This is a rare case of heterochronic genetic change to an ALK gene rearrangement in EGFR mutant lung adenocarcinoma.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/6996}
}